Pulmonx Corporation

NasdaqGS:LUNG Stock Report

Market Cap: US$96.1m

Pulmonx Management

Management criteria checks 4/4

Pulmonx's CEO is Glen French, appointed in Oct 2025, has a tenure of less than a year. total yearly compensation is $717.22K, comprised of 27.3% salary and 72.7% bonuses, including company stock and options. directly owns 2.24% of the company’s shares, worth $2.15M. The average tenure of the management team and the board of directors is 3.9 years and 6 years respectively.

Key information

Glen French

Chief executive officer

US$717.2k

Total compensation

CEO salary percentage27.27%
CEO tenureless than a year
CEO ownership2.2%
Management average tenure3.9yrs
Board average tenure6yrs

Recent management updates

Recent updates

Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified

Dec 05
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Aug 28
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward

Jul 24
Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward

Pulmonx Corporation (NASDAQ:LUNG) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 26
Pulmonx Corporation (NASDAQ:LUNG) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 29%

Apr 11
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 29%
User avatar

LungTrax And Global Expansion Will Broaden Market Access

Expansion into new markets and innovative tools like LungTrax could grow patient volume, boosting revenue and operational efficiency.

Pulmonx Corporation (NASDAQ:LUNG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 21
Pulmonx Corporation (NASDAQ:LUNG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Many Still Looking Away From Pulmonx Corporation (NASDAQ:LUNG)

Feb 07
Many Still Looking Away From Pulmonx Corporation (NASDAQ:LUNG)

Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%

Oct 22
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Oct 02
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 15
Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Pulmonx: Low Bar For Q2 Earnings

Jul 21

Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch

Jun 07
Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch

Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion

Apr 04
Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion

Pulmonx: Revisiting Thesis Following Management Change

Mar 26

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Feb 23
Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

Aug 01
Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

CEO Compensation Analysis

How has Glen French's remuneration changed compared to Pulmonx's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$57m

Jun 30 2025n/an/a

-US$57m

Mar 31 2025n/an/a

-US$57m

Dec 31 2024US$717kUS$196k

-US$56m

Sep 30 2024n/an/a

-US$57m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$59m

Dec 31 2023US$6mUS$580k

-US$61m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$5mUS$569k

-US$59m

Sep 30 2022n/an/a

-US$58m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$5mUS$550k

-US$49m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$3mUS$443k

-US$32m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$1mUS$412k

-US$21m

Compensation vs Market: Glen's total compensation ($USD717.22K) is about average for companies of similar size in the US market ($USD587.00K).

Compensation vs Earnings: Glen's compensation has been consistent with company performance over the past year.

CEO

Glen French (63 yo)

less than a year
Tenure
US$717,220
Compensation

Mr. Glendon E. French, also known as Glen, has been an Independent Director of EDAP TMS S.A. since February 27, 2025. He had been Chief Executive Officer and President at Pulmonx Corporation since December...

Leadership Team

NamePositionTenureCompensationOwnership
Glendon French
CEO, President & Directorless than a yearUS$717.22k2.24%
$ 2.2m
David Lehman
General Counsel & Secretary5.3yrsUS$1.49m0.20%
$ 188.1k
Derrick Sung
CFO & COOless than a yearUS$2.68m0.33%
$ 315.3k
Sri Radhakrishnan
Chief Science & Technology Officer6yrsno data0.078%
$ 74.5k
Marcee Maroney
Vice President of Marketingno datano datano data
Sarah Huber
Vice President of Sales (U.S.)3.9yrsno datano data
Lisa Paul
Chief People Officer4yrsno datano data
Jérôme Erath
Senior VP & GM of Internationalno datano datano data
Geoffrey Rose
Chief Commercial Officer6yrsUS$1.96m0.53%
$ 513.2k
Narinder Shargill
Senior Vice President of Global Medical & Clinical Affairsless than a yearno datano data
John McKune
VP of Finance & Corporate Controller1.8yrsno datano data
3.9yrs
Average Tenure
58yo
Average Age

Experienced Management: LUNG's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Glendon French
CEO, President & Director11.1yrsUS$717.22k2.24%
$ 2.2m
Dana Mead
Independent Chairperson of the Board15.9yrsUS$199.99k0.16%
$ 155.3k
Richard Ferrari
Independent Director18.1yrsUS$169.99k0.12%
$ 116.2k
Georgia Garinois-Melenikiotou
Independent Director5.3yrsUS$169.99k0.15%
$ 145.8k
Thomas Burns
Independent Director5.3yrsUS$157.49k0.088%
$ 84.5k
Daniel Florin
Independent Director6yrsUS$177.49k0.23%
$ 218.8k
Tiffany Sullivan
Independent Director4.5yrsUS$154.99k0.092%
$ 88.6k
6.0yrs
Average Tenure
64yo
Average Age

Experienced Board: LUNG's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/07 05:13
End of Day Share Price 2026/01/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pulmonx Corporation is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Travis SteedBofA Global Research
William PlovanicCanaccord Genuity
John YoungCanaccord Genuity